Paroxysmal Atrial Tachycardia Market Size was valued at USD 5.83 Billion in 2023. The Global Paroxysmal Atrial Tachycardia industry is projected to grow from USD 6.48 Billion in 2024 to USD 10.23 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.76% during the forecast period (2024 - 2032).
Paroxysmal atrial tachycardia is irregular heartbeat and is a type of atrial arrhythmia where the episode of arrhythmia begins and ends abruptly. Paroxysmal atrial tachycardia (PAT) is also known as paroxysmal supraventricular tachycardia (PSVT). PAT increases heart rate from 60 to 100 beats per minute (bpm) to between 130 and 230 bpm with infants demonstrating heart rate greater than 220 bpm.
PAT is the most common form of tachycardia in infants and children. Symptoms of PAT may include palpitations, lightheadedness, sweating, shortness of breath, chest pain and others. PAT is not usually a life-threatening disorder and the symptoms subside on their own. However, in rare cases, PAT may cause unconsciousness, congestive heart failure, cardiomyopathy and cardiac arrest. Having other heart issues such heart attacks or valve disease increase risk for PAT.
The cause of PAT are unknown but risk factors include alcohol, caffeine, nicotine, psychological stress, and Wolff-Parkinson-White syndrome. PAT occurs when electrical signals starting in the heart’s atria fire irregularly which affects the electrical signals transmitted from the sinoatrial node. This irregular beating prevents your heart from having enough time to fill with blood before pumping blood resulting in the body not receiving enough blood or oxygen. Women are at a higher risk for PAT than men.
Some of the key players profiled in the report are:
Intended Audience
The market drivers for paroxysmal atrial tachycardia market are rise in demand due to growing older population, increasing screening, greater emphasis on cardiac treatment, urgency of the paroxysmal atrial tachycardia treatment, rise in risk factors and others. The market restraints are the complications such as risk of bleeding, infections, pain, especially during surgery, high cost of paroxysmal atrial tachycardia treatment, lack of cardiac care infrastructure, and lack of focus on other diseases by the developing regions and others.
The paroxysmal atrial tachycardia market has been segmented on the basis of types, condition, diagnosis, drugs, surgery and end user.
Based on the types, the paroxysmal atrial tachycardia market has been segmented as AV nodal re-entrant tachycardia (AVNRT), AV reciprocating tachycardia (AVRT), and paroxysmal atrial tachycardia.
Based on the diagnosis, the paroxysmal atrial tachycardia market has been segmented as electrocardiogram (ECG), echocardiogram, blood tests, and electrophysiology study (EPS) and others.
Based on the treatment, the paroxysmal atrial tachycardia market has been segmented as calcium channel blockers, digoxin, beta-blockers, anti-arrhythmic medications, surgical ablation and others.
Based on the end user, the paroxysmal atrial tachycardia market has been segmented as hospitals and clinics, research and academics and others.
The Americas account for a significant market share owing to high expenditure on the health care especially in the U.S. and Canada. Additionally, the greater number of cardiac procedures due to greater healthcare penetration in the U.S. and Canada drives the paroxysmal atrial tachycardia market. The high concentration of the major hospitals in the developed countries of this region coupled with good reimbursement rates is also adding fuel to the market growth. Moreover, the large share of cardiac procedures especially the cardiac surgery treatment in the returns of hospitals favors the market. The large number of pharmaceutical companies in the U.S. is also a cause for the faster development of paroxysmal atrial tachycardia market in the U.S. The high development of microsurgery field in developed regions such as the U.S. and Europe is a strong driver of the market.
Europe is the second largest market in the world due to growing pharmaceutical industry and healthcare penetration. The European market growth is led by countries such as Germany and France. Germany is expected to be the fastest growing market over the assessment period due to its large pharmaceutical and microsurgery devices industry.
Asia Pacific region is expected to grow rapidly; China and India are likely to lead this market due to the fast growing healthcare sector and large unmet needs over the forecast period. South East Asian countries such as China, India, and Malaysia are projected to contribute highly to the market growth. The growing penetration of healthcare industry in the Asia Pacific region is expected to drive the future paroxysmal atrial tachycardia market in the region. However the low expenditure on cardiac and eye care coupled with the lack of insurance penetration in the developing regions is a dent on the market.
Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a poor growth owing to poor economic and political conditions, and poor healthcare development. Other regions are expected to be laggards due to poor social development and tribal identities such as sub Saharan Africa. The focus of the governments of poor countries on fulfilling basic healthcare relegates the paroxysmal atrial tachycardia market to the background which hampers the development of the market.
The report for Paroxysmal Atrial Tachycardia Market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.
| Report Attribute/Metric | Details |
| Market Size | 2032: USD 10.23 Billion |
| CAGR | 6.76% (2024-2032) |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2022 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Types, Condition, Diagnosis, Drugs, Surgery and End user |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Abbott Laboratories, Reliant Pharmaceuticals, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, GlaxoSmithKline plc, GE Healthcare, Glenmark Pharmaceuticals, Koninklijke Philips N.V., ANI Pharmaceuticals, Inc., Medtronic, Inc., Microport Scientific Corporation, St. Jude Medical, Inc., and Siemens AG and others |
| Key Market Opportunities | New product launches and R&D Amongst major key Players |
| Key Market Drivers | Rise in demand due to growing older population Increasing screening Greater emphasis on cardiac treatment Urgency of the paroxysmal atrial tachycardia treatment Rise in risk factors and others |
Paroxysmal Atrial Tachycardia Market Highlights:
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
